p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies-Reference-Cited by-同舟云学术

p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies

Published:2012-02 Issue:1 Volume:39 Page:97-108
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Saunthararajah Yogen,Triozzi Pierre,Rini Brian,Singh Arun,Radivoyevitch Tomas,Sekeres Mikkael,Advani Anjali,Tiu Ramon,Reu Frederic,Kalaycio Matt,Copelan Ed,Hsi Eric,Lichtin Alan,Bolwell Brian

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference152 articles.

1. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies;Wattel;Blood,1994

2. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia;Stirewalt;Blood,2001

3. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents;Andersen;Genes Chromosomes Cancer,2001

4. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile;Schoch;Genes Chromosomes Cancer,2005

5. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition;Wendel;Proc Natl Acad Sci U S A,2006

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

2. A review on regulation of DNA methylation during post-myocardial infarction;Frontiers in Pharmacology;2024-02-13

3. Differentiating Acute Myeloid Leukemia Stem Cells/Blasts;Reference Module in Biomedical Sciences;2024

4. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine;Methods in Cell Biology;2024

5. Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-08